Eversana Intouch

FEBRUARY 1, 2023

Are those ‘seamless brand experiences’ integrating the right mix of digital tools and one-on-one personal engagements actually accelerating patients’ time to therapy and delivering business impact? Are more prescriptions being written and fulfilled to validate the time, money, and resoures allocated?

Prescription 59

Prescription Marketing Manufacturing Pharma 59

PharmaTech

JUNE 27, 2022

Patient recruitment, retention, diversity, & safety are all factors driving the need for radical innovation in clinical research. Your research teams can experience benefits such as; improved patient experience, higher quality outcomes data, & savings of US$25,000,000+ for individual studies. Download the White Paper now.

Recruitment 40

Recruitment Safety Patients 40

Pharmaceutical Technology

DECEMBER 8, 2022

Directed against a cell membrane protein called CD19, Yescarta uses the immune system of the patient to destroy cancer. It is created by taking T cells from the patient’s blood and then engineered in the laboratory to express chimeric antigen receptors. . Optimise your cell therapy process: a guide to cell thawing.

Manufacturing 122

Manufacturing Marketing Engineering Patients 122

Pharmaceutical Technology

JANUARY 17, 2023

It could be used for T-Cell Acute Lymphoblastic Leukaemia (T-ALL) treatment in patients for whom bone marrow transplantation and chemotherapy failed to work. Dr Alvarez-Vallina said: “It is necessary to develop strategies addressed to very specific targets for each disease and adapted for each patient. STAb-T therapy is on this path.”.

Specialization 110

Specialization Patients Pharmaceutical Leads 110

Pharmaceutical Technology

DECEMBER 21, 2022

The vaccine manufacturing facility will also offer National Health Service (NHS) patients access to the company’s Covid-19 vaccines that can provide protection against various variants. Additionally, the centre is anticipated to have to capacity to make up to 250 million doses of vaccines per year.

Government 140

Government Manufacturing Pharmaceutical Marketing 140

Pharmaceutical Technology

NOVEMBER 7, 2022

SHL Medical is a world-leading solutions provider for advanced drug delivery systems with a unified purpose to further enable patient independence. Growing demand for patient independence. Consequently, pharmaceutical and biotech companies are increasingly looking to provide devices that allow patients to self-administer drugs.

Medical 52

Medical Patients Transportation Manufacturing 52

Pharmaceutical Technology

FEBRUARY 16, 2023

The MOS platform enables translational research on micro-tumours derived from patients with new capabilities. It enables quick evaluation of a patient tumour response to a range of cancer drug modalities within 14 days of obtaining harvested samples of tumour cells.

Pharmaceutical 96

Pharmaceutical Patients Medicine Leads 96

Pharmaceutical Technology

MARCH 8, 2023

The multi-year collaboration aims to develop new technologies which will help in improving clinical outcomes for patients. We are delighted to be partnering with the CAR T pioneers at Penn and believe that combining our expertise in science and technology will help bring the next generation of cell therapies to patients faster.”

Food and Drug Administration 97

Food and Drug Administration Manufacturing Engineering Food 97

Pharmaceutical Technology

MARCH 10, 2023

The representative expected the facility to open more treatment opportunities for UK citizens saying, “It will help give patients quick access to the latest treatments by increasing the number of UK patients with incurable diseases who are able to take part in clinical trials and bring new treatments into the NHS faster.”

Manufacturing 105

Manufacturing Distribution Medicine Patients 105

Pharmaceutical Technology

NOVEMBER 29, 2022

With a shared mission of making cell therapies available to solid tumour patients, the capabilities of Neogene in TCR-T discovery, development and production will bolster the goal of AstraZeneca to transform patient outcomes. The takeover will offer AstraZeneca access to TCR-Ts, which possess the potential for fighting solid tumours.

Manufacturing 111

Manufacturing Leads Patients Pharmaceutical 111

Pharmaceutical Technology

FEBRUARY 9, 2023

ReviR combines computational and high throughput drug discovery technologies to deliver advanced medicines to patients. Our BindeR and SpliceR platform technologies have the potential to advance therapeutics for undruggable cancer targets, and we believe this collaboration will accelerate the discovery of new treatments for patients.”

Biopharma 96

Biopharma Pharmaceutical Patients Marketing 96

Pharmaceutical Technology

DECEMBER 23, 2022

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. Optimise your cell therapy process: a guide to cell thawing.

Medicine 131

Medicine Pharmaceutical Marketing Sales 131

Pharmaceutical Technology

MARCH 20, 2023

With this collaboration, we want to develop mRNA vaccine product candidates with the potential to improve the lives of patients who suffer from certain autoimmune diseases and allergies.” RVAC Medicines CEO Dr Sean Fu said: “We are excited to begin this collaboration with Dr Weissman, a pioneer in the field of mRNA vaccines and therapeutics.

Medicine 98

Medicine Food Leads Patients 98

Pharmaceutical Technology

FEBRUARY 23, 2023

Free Whitepaper Optimise your cell therapy process: a guide to cell thawing Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer.

Manufacturing 115

Manufacturing Medicine Consulting Pharmaceutical 115

pharmaphorum

AUGUST 24, 2022

It was compared in the study to an already-available free app – TMSOFT’s White Noise Lite – which is described by the researchers as “a popular self-help passive sound therapy app.” The results have just been published in the journal Frontiers in Neurology.

Recruitment 52

Recruitment Physicians Patients FDA 52

Pharmaceutical Technology

DECEMBER 12, 2022

Gilead company Kite has entered an international strategic partnership with Arcellx for the joint development and commercialisation of the latter’s T-cell therapy, CART-ddBCMA, to treat relapsed or refractory multiple myeloma patients. Most importantly, this collaboration is focused on accelerating access for patients in need.”.

Manufacturing 105

Manufacturing Marketing Pharmaceutical Patients 105

Pharmaceutical Technology

JANUARY 5, 2023

Prevail and Capsida are committed to developing highly effective and safe gene therapies that have the potential to be transformative for patients living with serious CNS diseases.”. According to the deal, Capsida will get $55m, comprising an upfront payment and a commitment to participate in its next funding round.

Engineering 95

Engineering Leads Pharmaceutical Marketing 95

Clarivate

FEBRUARY 28, 2024

These conditions, affecting small patient populations and characterized by diverse clinical manifestations, demand innovative approaches and cutting-edge technologies to drive research and commercialization forward. This subject is discussed in a forthcoming white paper from Clarivate.

Electronics 59

Electronics Healthcare Healthcare Medicine 59

Pharmaceutical Technology

MARCH 28, 2023

This guide addresses how cell thawing has historically developed into the new techniques used today, along with the physical and biological implications of key metrics and components such as warming rate and ice structure.

Pharmaceutical 94

Pharmaceutical Leads Marketing Patients 94

Impetus Digital

JANUARY 13, 2023

Patient-centricity taking center stage. In the near future, we will see a broad expansion of medical engagement across providers, patients, and other stakeholders. In 2023, we will see Medical Affairs engage both patients and payers more than in previous years. Patient-centricity will become the rule rather than the exception.

Pharma 109

Pharma Medical Patients Healthcare 109

Pharmaceutical Technology

DECEMBER 18, 2022

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. Optimise your cell therapy process: a guide to cell thawing.

Medicine 121

Medicine Marketing Pharmaceutical Leads 121

Pharmaceutical Technology

DECEMBER 5, 2022

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. Optimise your cell therapy process: a guide to cell thawing.

Government 98

Government Pharmaceutical Marketing Leads 98

Pharmaceutical Technology

JANUARY 27, 2023

The chimeric antigen receptor T-cell (CAR-T) therapy axicabtagene ciloleucel has been recommended for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL) in adult patients who have previously received two or more lines of systemic therapy.

Medicine 59

Medicine Patients Pharmaceutical Leads 59

Pharmaceutical Technology

JANUARY 10, 2023

Under the deal terms, Boehringer Ingelheim will be responsible for providing patient-derived TCR data to fuel the target discovery efforts of 3T Biosciences for identifying antigens leveraging its 3T TRACE discovery platform. The company will receive an undisclosed upfront payment and research and development support.

Engineering 52

Engineering Patients Sales Leads 52

Pharmaceutical Technology

MARCH 1, 2023

Tevard Biosciences and Vertex Pharmaceuticals have announced a four-year global research partnership to develop new tRNA-based therapies to treat Duchenne muscular dystrophy (DMD) patients. The deal offers access to the platforms of Tevard to discover and develop tRNA-based therapies.

Manufacturing 52

Manufacturing Pharmaceutical Patients Leads 52

Pharmaceutical Technology

DECEMBER 20, 2022

Japan has granted approval for Bristol-Myers Squibb ’s (BMS) Breyanzi (lisocabtagene maraleucel; liso-cel) as second-line therapy to treat relapsed or refractory (r/r) large B-cell lymphoma (LBCL) patients. The treatment is indicated for usage in such patients irrespective of autologous hematopoietic stem-cell transplantation status.

Patients 59

Patients Safety Pharmaceutical Leads 59

Pharmaceutical Technology

JANUARY 12, 2023

Solid Biosciences president and CEO Bo Cumbo said: “This collaboration with Phlox Therapeutics is an exciting opportunity to work with a company that shares our commitment and innovative approach to bringing transformative therapies to patients with rare genetic diseases. Optimise your cell therapy process: a guide to cell thawing.

Manufacturing 52

Manufacturing Pharmaceutical Patients Medicine 52

Pharmaceutical Technology

JANUARY 11, 2023

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. Optimise your cell therapy process: a guide to cell thawing.

Leads 59

Leads Pharmaceutical Marketing Sales 59

Clarify Health

JUNE 16, 2021

“My patients are different.” Therefore, any solution that aspires to create fair provider performance benchmarks will need to first address the physician’s inherent (and valid) argument, “my patients are different”. Read our latest white paper The Future of Benchmarking. Precise modeling using machine learning.

Healthcare 52

Healthcare Healthcare Physicians Patients 52

Medical Device Success

JUNE 5, 2017

They can lend credibility to the claims you make related to your products.

Medical 130

Medical Marketing Management Doctors 130

pharmaphorum

JULY 5, 2022

Trial organisers face intense competition to find and recruit eligible patients for atopic dermatitis studies. Instead, atopic dermatitis clinical trial organisers often simply only reach out to a limited patient population and fail to reach the complete, diverse, patient population of atopic dermatitis.

Recruitment 99

Recruitment Competition Patients Marketing 99

Impetus Digital

DECEMBER 5, 2022

The industry is under immense pressure to adopt new technologies and systems that can protect patient data while allowing easy sharing with authorized parties. Too much security can make it difficult for patients to get the care they need, while too little security can leave patient data vulnerable to theft and misuse.

Healthcare 94

Healthcare Healthcare Medical Electronics 94

Pharmaceutical Technology

DECEMBER 14, 2022

Our work together will focus on developing the targeted template and manufacturing for viral vectors in order to bring these life-changing therapies to more patients.”. Optimise your cell therapy process: a guide to cell thawing.

Manufacturing 52

Manufacturing Engineering Education Training 52

Pharmaceutical Technology

FEBRUARY 23, 2023

Free Whitepaper Optimise your cell therapy process: a guide to cell thawing Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer.

Engineering 59

Engineering Pharmaceutical Manufacturing Medicine 59

eMediWrite

SEPTEMBER 12, 2022

Select Relevant White Paper Topics. White papers are supposed to educate your target audience, therefore you must first decide if you are writing for your patients or colleagues. White papers have historically listed the advantages and attributes of a specific good or service.

Medical 52

Medical Sales pitches Education Doctors 52

Pharmaceutical Technology

MARCH 27, 2023

Free Whitepaper Optimise your cell therapy process: a guide to cell thawing Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer.

Manufacturing 52

Manufacturing Government Competition Networking 52

Pharmaceutical Technology

NOVEMBER 30, 2022

Typically carried out at the point of care, errors in cell therapy thawing could compromise treatment efficacy, leading to significant patient impact as well as high costs and a compromised reputation for the product’s developer. Optimise your cell therapy process: a guide to cell thawing.

Government 59

Government Medical Pharmaceutical Leads 59